-
-
-
-
-
-
-
Ligand Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
-
-
-
-
-
-
-
Ligand Pharma (LGND) PT Raised to $162 at Oppenheimer
-
-
-
-
-
-
-
Ligand Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Ligand Reports Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Ligand Pharma (LGND) Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
-
-
-
-
-
-
-
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
-
1,164,407 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

